Emergent BioSolutions reported $290.1M in Trade Debtors for its fiscal quarter ending in June of 2023.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 178.32M 11.98M Sep/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
ALKERMES USD 459.09M 2.61M Sep/2026
Alnylam Pharmaceuticals USD 1.08B 172.17M Sep/2026
Amarin USD 126.83M 477K Dec/2025
ANI Pharmaceuticals USD 304.45M 29.98M Sep/2026
BioMarin Pharmaceutical USD 1.08B 15.31M Sep/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Emergent BioSolutions USD 290.1M 134.2M Jun/2023
Exelixis USD 328.47M 6.25M Sep/2026
Glaxosmithkline GBP 11.31B 814.23M Sep/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Ionis Pharmaceuticals USD 88M 29.15M Sep/2026
Ironwood Pharmaceuticals USD 81.89M 5.68M Dec/2024
Lexicon Pharmaceuticals USD 2.38M 50K Dec/2025
Lonza CHF 1.78B 55M Dec/2025
Merck USD 12.56B 354M Jun/2026
Moderna USD 1.37B 1.35B Sep/2026
Myriad Genetics USD 115.3M 2.7M Dec/2025
Nektar Therapeutics USD 3.6M 1.82M Mar/2026
Neurocrine Biosciences USD 957.3M 70.3M Sep/2026
Pfizer USD 17.57B 1.38B Sep/2026
PTC Therapeutics USD 239.04M 19.12M Jun/2026
Sanofi EUR 326M 166M Sep/2026
Sarepta Therapeutics USD 385.98M 7.82M Sep/2026
United Therapeutics USD 348.6M 38.3M Sep/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024